The TCGA data supported our initial patient cohort data with an increase in SRSF3 expression, downregulation of CDKN1A levels and upregulation of miRNAs of the miR‐17‐92 cluster in tumour samples compared with normal tissue, with the largest increase in miR‐17 and miR‐20a levels (Fig 6F and G). The gene discussed is SRSF3; the disease is neoplasm.